In this issue:
Adjuvant nivolumab + ipilimumab or nivolumab monotherapy vs placebo in resected stage IV melanoma with no evidence of disease
Long-term outcomes to retreatment in melanoma patients treated with PD-1 blockade
Incidence and predictors of CNS metastasis for patients with stage III melanoma
Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy
Impact of preceding radiotherapy on the outcome of ICI in metastatic melanoma
Nivolumab + ipilimumab alone or with local therapy in patients with melanoma brain metastasis
QOL in long-term survivors of advanced melanoma treated with ICIs
20-year assessment of metastatic latency and time to death after proton therapy for uveal melanomas
Late recurrence of melanoma after 10 years and disease course
Please login below to download this issue (PDF)